Skip to main content

Brain Energy Metabolism and Sleep in Adults


The first phase of this study will investigate the relationship of sleep abnormalities, genes, and brain energy with cognitive performance among people who are cognitively normal, have mild cognitive impairment, or have Alzheimer's disease. The second phase will test the effects of an oral airway management system on sleep and cognition.

Minimum Age Maximum Age Gender Healthy Volunteers
55 Years 85 Years All Yes
November 30, 2018
July 31, 2021

  • At least 12 years of education
  • Right-hand dominant
  • With or without minor memory complaints
  • Participants who can safely have a magnetic resonance imaging (MRI) scan
  • Have motor abilities including the use of the right arm and hand for neuropsychological testing
  • Able to speak, read, and comprehend English fluently (testing and training material are validated in English)
  • Non-pregnant and not on hormone replacement therapy

  • Neurological disorders (e.g., stroke, brain tumor, or cerebral hemorrhage)
  • Autoimmune disorders such as fibromyalgia, systemic lupus erythematosus, multiple sclerosis, and rheumatoid arthritis
  • Metabolic diseases such as diabetes mellitus or thyroid disorders that are not currently managed by a physician
  • Psychiatric disorders such as bipolar disorder, major depressive disorder, pervasive developmental disorder, schizophrenia, and anxiety disorder
  • Current drug or alcohol abuse
  • Head injuries that may have resulted in traumatic brain injury
  • Cancer treated with radiation and/or chemotherapy
  • General anesthesia within past 6 months
  • Uncorrected vision and hearing problems
  • Active pain requiring treatment
  • Body mass index of 35
  • Previously diagnosed sleep disorders
  • Known chronic obstructive pulmonary disease
  • Exclusion criteria for MRI: Permanent makeup; metal implants, bullets, or shrapnel; certain medical devices such as a pacemaker; or hearing aid that cannot be removed

Participants will complete neurocognitive testing, genetic testing for Alzheimer's risk genes ApoE4 and ABCA7, a sleep assessment, and an MRI scan. For the second phase of the study, participants with abnormal sleep and upper airway obstruction will be invited to use the myTAP device for 3 months followed by neurocognitive testing and sleep assessment. myTAP is approved by the U.S. Food and Drug Administration for the treatment of snoring and obstructive sleep apnea.

Name City State Zip Status Primary Contact
Center for BrainHealth, The university of Texas at Dallas
Dallas Texas 75235 Recruiting Namrata Das, MD,MPH

The University of Texas at Dallas

  • Texas A & M University Baylor College of Dentistry
  • University of Texas, Southwestern Medical Center at Dallas

Name Phone Email
Namrata Das, MD 972-883-3266
Sandi Chapman, PhD 972-883-3407


Brain Energy Metabolism and Sleep in Adults